Brief: United Laboratories Says Application For Clinical Trial Of Class 1 New Drug Tul12101 Eye Drops Approved
03/03/2023 11:47
March 3 (Reuters) - United Laboratories International
Holdings Ltd 3933.HK :
* APPLICATION FOR CLINICAL TRIAL OF CLASS 1 NEW DRUG
TUL12101 EYE
DROPS APPROVED BY CHINA NMPA
Source text for Eikon: ID:nHKS75Q4T6
Further company coverage: 3933.HK
Recent news on United Laboratories International Holdings
See all newsBrief: United Laboratories International Receives Milestone Payment From Novo
Brief: United Laboratories International Says NMPA Accepts Insulin Degludec And Liraglutide Injection Marketing Registration Application
Brief: United Laboratories International Posts HY Profit Attributable RMB 347.6 Million
China's United Laboratories half-year profit drops 82%
Brief: United Laboratories International Expects HY Net Profit RMB 340 Million